Insmed Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.86%.
Did INSM Beat Earnings? Q2 2025 Results
Insmed delivered a mixed second quarter for 2025, posting revenue that edged past expectations while its bottom line fell short by a meaningful margin. The company reported $107.42 million in total revenue, beating the $104.31 million consensus by 2.97% and marking 18.9% growth year-over-year, fueled by record U.S. ARIKAYCE sales of $68.70 million and a 45.3% surge in Japan. But the earnings picture darkened on the cost side, with the net loss coming in at $1.70 per share, missing the $1.31 consensus estimate by 29.59%, as aggressive brensocatib launch readiness spending pushed SG&A to $154.76 million and total operating expenses to $420.29 million. The heavy investment reflects management's bet on a near-term inflection point, with brensocatib's PDUFA date set for August 12, 2025, and an immediate U.S. launch planned upon approval. Insmed reiterated its full-year ARIKAYCE revenue guidance of $405 million to $425 million, representing 11% to 17% growth, and expects cash burn to ease as brensocatib revenue begins contributing in coming quarters.
- ARIKAYCE U.S. achieved highest quarterly revenue ever driven by continued patient demand
- Japan and ex-U.S. ARIKAYCE strength driven by volumes supported by new targeting and patient experience strategies
- 19% year-over-year ARIKAYCE revenue growth across all geographic regions
- Three consecutive positive clinical trial results across all late-stage assets (ARIKAYCE, brensocatib, TPIP)
“The second quarter of 2025 heralded another important milestone for patients and Insmed, with the Phase 2b PAH study of TPIP yielding topline results that surpassed our expectations. Insmed is now 'three for three' in terms of positive clinical trial results for our late-stage assets, and we have a line-up of additional anticipated milestones with the potential to expand our impact on patients expected over the next twelve months.”
Insmed CEO, on the earnings call
Forward Guidance & Outlook
Insmed reiterates full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million, representing 11% to 17% year-over-year growth. The company expects cash burn to decrease in coming quarters with the anticipated U.S. launch of brensocatib. Key upcoming milestones include: PDUFA target action date of August 12, 2025 for brensocatib NDA in bronchiectasis with immediate U.S. launch planned upon approval; Phase 2b BiRCh topline data for brensocatib in CRSsNP by year-end 2025; Phase 3 TPIP study initiation in PH-ILD in H2 2025 and PAH in early 2026; Phase 2b CEDAR interim futility analysis in HS in Q1 2026; Phase 3 ENCORE readout for ARIKAYCE in H1 2026; and regulatory submissions for brensocatib in Japan in H2 2025 with European/UK/Japan commercial launches anticipated in 2026.
INSM YoY Financials
INSM Revenue by Segment
INSM Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.